Plain-English translation of NCT05908682 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking the safety of ibrexafungerp (Brexafemme), a medication used to treat vaginal yeast infections, in pregnant women and their babies. Researchers want to understand how the medication may affect pregnancy and infant health by collecting information about outcomes for both mother and baby over the first year of life.
When pregnant women take any new medication, it's important to monitor whether it affects the baby's development and health. This medication is relatively new, so this study helps doctors understand whether it is safe to use during pregnancy and what, if any, effects it might have on newborns and infants.
You likely qualify if…
You likely don't qualify if…
You would participate by sharing your pregnancy and medical history through interviews and questionnaires, either by calling the study team directly or working with your healthcare provider. The study team will collect information about your pregnancy, delivery, and your baby's health from birth through one year of age. This is a monitoring study, not a treatment study—you've already taken the medication, and researchers simply want to follow up to ensure everything is going well.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
India
Sponsor
GlaxoSmithKline
Enrollment target
~100 participants
Started
November 2025
Primary completion
July 2029
Age range
0 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sanjeev Miglani, MD
GlaxoSmithKline
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.